Regulation · United Kingdom

Is GHK-Cu legal
in the UK?

We found no UK law that lists GHK-Cu. The law asks what a product is for and how it is presented, and the answer differs for a cream and an injection. Here are the rules and the record, dated 18 November 2026.

Short answerRegulation · 7 min read · Updated 18 Nov 2026

We found no UK law that names GHK-Cu; the MHRA classifies finished products, not ingredients. As copper tripeptide-1 it is a cosmetic ingredient, but no product intended for injection can be a cosmetic. A product presented as preventing or treating disease, or used to modify a physiological function by a pharmacological, immunological or metabolic action, is a medicine.

Key takeaways

  • GHK-Cu is not a controlled drug: Schedule 2 to the Misuse of Drugs Act 1971 does not name it. The MHRA classifies finished products, not individual substances.
  • Cosmetics law covers products placed on the outside of the body mainly to clean, perfume, change the appearance of, protect or keep it in good condition, and excludes anything “intended to be ingested, inhaled, injected or implanted”.
  • Medicines law applies to a product presented as preventing or treating disease, or used to modify a physiological function by a pharmacological, immunological or metabolic action; an unauthorised medicinal product may not be sold or supplied.
  • In March 2026 the MHRA told STV News it disregards “research purposes” claims used to avoid medicines regulations, and that where a product is a medicine without the right authorisation it takes compliance action, including removal from the UK market where necessary.
  • We found no MHRA determination, notice or statement naming GHK-Cu, and the UK medicines compendium lists no medicine under its names (18 Nov 2026).

01What does UK law say about GHK-Cu?

We found no UK law that names GHK-Cu, and no UK regulator decision about it. Two regimes can apply, and which one depends on the product, not the molecule.

The MHRA’s guide to what counts as a medicine, Guidance Note 8, says the agency “only classifies finished products and not individual substances and ingredients”. So one peptide can sit in a cream regulated as a cosmetic and in a product regulated as a medicine. GHK-Cu’s cosmetic ingredient name is copper tripeptide-1, and prezatide copper is another name for it.

GHK-Cu is not a controlled drug: Schedule 2 to the Misuse of Drugs Act 1971 does not name it. The hormones UK drug law does control, and the wider rules, are on peptides and UK law.

02When is a GHK-Cu product a cosmetic?

In Great Britain, cosmetics fall under the UK Cosmetics Regulation, the retained version of EU Regulation 1223/2009; Northern Ireland follows the EU Regulation itself. Article 2(1)(a) defines a cosmetic product as:

“any substance or mixture intended to be placed in contact with the external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours”

Article 2(2) draws the line on route: “a substance or mixture intended to be ingested, inhaled, injected or implanted into the human body shall not be considered to be a cosmetic product.” Under that article, a GHK-Cu product intended for injection cannot be a cosmetic product.

The Regulation’s lists of prohibited substances (Annex II) and restricted substances (Annex III), as published on legislation.gov.uk, do not name GHK-Cu, copper tripeptide-1 or prezatide (read 18 November 2026).

Being a cosmetic carries its own duties. The Office for Product Safety and Standards says every cosmetic product needs a responsible person with a UK address, a safety assessment by a qualified safety assessor, and notification to OPSS before it reaches consumers, and that the responsible person must report serious harmful effects and “be able to prove that any claims made when marketing the product are correct”. Article 20(1) adds that text, names and pictures “shall not be used to imply that these products have characteristics or functions which they do not have”. How these rules apply to skincare peptides generally: peptides in skincare.

03When is a GHK-Cu product a medicine?

Regulation 2 of the Human Medicines Regulations 2012 gives two routes in. A medicinal product is (a) “any substance or combination of substances presented as having properties of preventing or treating disease in human beings”, or (b) one that “may be used by or administered to human beings with a view to” “restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action”, or making a medical diagnosis. Regulation 46 then says: “A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product.”

For products on the line between cosmetic and medicine, Guidance Note 8 says “the MHRA will apply the tests set out in The Human Medicines Regulations 2012”. Among the factors it lists for the presentation test are claims on labels, websites and social media, and “the product form, (capsule, tablet, injection etc.) and the way it is to be used”. For the function test it lists, among others, how the product is used, its form, and “the risks which use of the product may pose”. The MHRA’s borderline guidance, updated 2 July 2026, puts it in one line: the MHRA decides whether “the claims that are made or the active substance(s) present” mean a product should be regarded as a medicinal product.

What the MHRA has said about peptides. In March 2026 the MHRA’s head of borderlines, Lynda Scammell, gave STV News a statement: “We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations.” It added: “If there is evidence within the promotional material that the products are in fact unauthorised medicines intended for human use, we will take appropriate regulatory action.” Where a product is classified as a medicine and is not appropriately authorised, it said, the MHRA takes compliance action, “including the removal of the product from the UK market where necessary”. The statement does not name GHK-Cu. What a “research use only” label does and does not do: research use only.

What the record shows. We found no MHRA decision on a GHK-Cu product. The MHRA’s list of final borderline determinations (December 2023 edition) and its list of regulation 165 notices (October 2019 to May 2023) do not mention GHK-Cu, copper or peptides. The UK electronic medicines compendium (emc) returned no medicine for “GHK”, “GHK-Cu”, “copper tripeptide” or “prezatide”, while a control search for somatropin returned 21 results (all searched 18 November 2026).

04What have UK regulators done about GHK-Cu, and when?

A dated record of the UK documents that bear on GHK-Cu. None of them names it.

DateWhat happenedSource
30 Nov 2009EU Regulation 1223/2009 on cosmetic products adopted. Its retained version is the UK Cosmetics Regulation in Great Britain, with Article 2(2) excluding anything intended to be injectedMHRA Guidance Note 8
2012Human Medicines Regulations 2012 consolidate UK medicines law: regulation 2 defines a medicinal product, regulation 46 bars selling or supplying an unauthorised onelegislation.gov.uk
Dec 2023Latest edition of the MHRA’s list of final borderline determinations (Volume 5, from January 2016): no entry mentions GHK-Cu, copper or peptidesMHRA
Sep 2025MHRA publishes the current Guidance Note 8: it classifies finished products, not substances, and applies the medicines tests to cosmetic borderline casesMHRA Guidance Note 8
19 Mar 2026MHRA’s head of borderlines tells STV News the agency disregards “research purposes” claims used to avoid medicines regulations, and takes compliance action, including removal from the UK market, against medicines without the right authorisationSTV News (press report of an MHRA statement)
2 Jul 2026MHRA updates its borderline-products guidanceGOV.UK
18 Nov 2026Our checks: no MHRA determination, notice or GOV.UK page naming GHK-Cu found; the emc lists no medicine under its names; the UK Cosmetics Regulation’s prohibited and restricted lists do not name itSearches listed in Sources
1 Jan 2027WADA’s 2027 Prohibited List takes effect; it does not name GHK-CuWADA

Changes to UK peptide rules are logged in our regulatory changelog.

05How is GHK-Cu treated in sport in the UK?

Sport has its own rulebook, and UK medicines law has no bearing on it. WADA’s Prohibited List does not name GHK-Cu, in the 2026 List or in the 2027 List that takes effect on 1 January 2027. Class S0 covers pharmacological substances with “no current approval by any governmental regulatory health authority for human therapeutic use”, and anti-doping organisations decide how it applies; WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. UK Anti-Doping is one of the agencies behind Global DRO, which gives information on medications against the current List. More: peptides and anti-doping and the GHK-Cu research guide.

06What we don’t know about GHK-Cu in the UK

  • How the MHRA would classify a particular GHK-Cu product. It decides product by product, and we found no published decision on one.
  • Whether any MHRA enforcement has involved GHK-Cu products. The MHRA documents and statements we read do not name it.
  • Whether the Northern Ireland position differs in practice. It follows the EU cosmetics rules, which this page does not cover in detail.
  • Whether the MHRA’s product licence database lists anything containing it. We searched the emc, not MHRA Products.

For the other markets: the US and Australia.

This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.

RefSources

  1. The Human Medicines Regulations 2012 (SI 2012/1916), regulations 2 (medicinal products) and 46 (requirement for authorisation). UK legislation, revised text, read 18 Nov 2026. www.legislation.gov.uk/uksi/2012/1916/regulation/2
  2. MHRA. Guidance Note 8: A guide to what is a medicinal product. Guidance, published September 2025; PDF linked from the borderline-products guidance, read 18 Nov 2026. assets.publishing.service.gov.uk/media/6a747082bde92a23046b2…
  3. MHRA. Borderline products: how to tell if your product is a medicine. Guidance, updated 2 Jul 2026; read 18 Nov 2026. www.gov.uk/guidance/borderline-products-how-to-tell-if-your-…
  4. MHRA. Final determinations made in accordance with regulation 3A, Volume 5 (from January 2016), December 2023 edition; and Notices issued under regulation 165 of the Human Medicines Regulations 2012, October 2019 to May 2023. Published lists, searched 18 Nov 2026. assets.publishing.service.gov.uk/media/659bfba3c23a1000128d0…
  5. Regulation (EC) No 1223/2009 on cosmetic products, as retained in Great Britain (UK Cosmetics Regulation): Article 2 as quoted in MHRA Guidance Note 8; Annexes II and III, legislation.gov.uk text (version of 19 Aug 2026). UK legislation, read and searched 18 Nov 2026. www.legislation.gov.uk/eur/2009/1223/annex/III
  6. Office for Product Safety and Standards. Making cosmetic products available to consumers in Great Britain. Guidance, published 4 Oct 2021; read 18 Nov 2026. www.gov.uk/guidance/making-cosmetic-products-available-to-co…
  7. Misuse of Drugs Act 1971, Schedule 2 (controlled drugs). UK legislation, revised text, searched 18 Nov 2026. www.legislation.gov.uk/ukpga/1971/38/schedule/2
  8. Flett A. The peptide boom: legal ‘loophole’ fuels rise of unregulated injectables (MHRA statement, Lynda Scammell). STV News, 19 Mar 2026. Press report of an MHRA statement; read 18 Nov 2026. news.stv.tv/scotland/the-peptide-boom-call-for-review-of-leg…
  9. Electronic medicines compendium (emc) searches for GHK, GHK-Cu, copper tripeptide and prezatide (no results) and somatropin (control, 21 results); GOV.UK site search for “GHK” (no page about the peptide). Database searches, 18 Nov 2026. www.medicines.org.uk/emc/search?q=GHK
  10. PubChem. Prezatide copper, CID 71587328: synonyms include copper tripeptide-1 and GHK copper. Compound record, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/71587328
  11. World Anti-Doping Agency. Prohibited List 2026 and Prohibited List 2027 (in force 1 Jan 2027), class S0. International Standard; both PDFs searched 18 Nov 2026. Global DRO home page (partners include UK Anti-Doping), read 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  12. World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes (S0, non-approved substances). Undated (the file name carries 17 Aug 2026); read at wada-ama.org 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is GHK-Cu a controlled drug in the UK?

No. Schedule 2 to the Misuse of Drugs Act 1971 does not name it. Medicines law and cosmetics law can still apply to products that contain it.

Is GHK-Cu a medicine in the UK?

It depends on the product. The MHRA classifies finished products: one presented as preventing or treating disease, or used to modify a physiological function by a pharmacological, immunological or metabolic action, is a medicinal product. The emc lists no medicine under GHK-Cu’s names (18 Nov 2026).

Can an injectable GHK-Cu product be a cosmetic in the UK?

No. The UK Cosmetics Regulation says a substance or mixture intended to be ingested, inhaled, injected or implanted “shall not be considered to be a cosmetic product”.

Does a “research use only” label change how the MHRA sees a product?

The MHRA told STV News in March 2026 that it disregards “research purposes” claims if it is clear they are being used as an attempt to avoid medicines regulations, and that it takes regulatory action where promotional material shows the products are unauthorised medicines intended for human use.

Is GHK-Cu banned in sport in the UK?

WADA’s 2026 and 2027 Prohibited Lists do not name it. Class S0 covers pharmacological substances with no current government approval for human therapeutic use, WADA says a peptide not named on the List “may still be prohibited”, and anti-doping organisations decide how it applies; check with UK Anti-Doping.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page